Маркеры, характеризующие гликемический статус и развитие нейрональных нарушений у пациентов с сахарным диабетом 1-го типа (1091720), страница 21
Текст из файла (страница 21)
Клеточная гибель бетаэндокриноцитов панкреатических островков, обусловленная аллоксановой цитотоксичностью //Бюллетень Волгоградского научного центра РАМН. – 2008. - V. 4. - c. 24-2530. Панков Ю. А., Кондратьев Я. Ю., Горскова Е А., Кеда Ю. М., Осипова Т. А.,Арбузова М. И., Садовникова Н. Е, Федотов Е П. Гипоинсулинемия, гипергликемия ициркулирующие аутоантитела к островковым клеткам при развитии стрептозотоциновогодиабета у крыс // Пробл. эндокринол.
- 1990. - T. 36. - N. 2. - C. 70-73.31. Kohnert K.D., Besch W., Schröder D., Ziegler B., Hehmke B., Fält K., Ziegler M.Detection of antibodies to islet cell and splenic lymphocytes in diabetes-prone BB and adjuvantstreptozotocin treated Lewis rats by ELISA and immunoblot analysis // Allerg Immunol (Leipz). –1990. - V.
36(4). – P. 321-33132. Vinik A.I., Park T.S., Stansberry K.B., Pittenger G.L. Diabetic neuropathies //Diabetologia. - 2000. – V. 43. – P. 957-97333. Hellweg R., Raivich G., Hartung H.D., et. al. Axonal transport of endogenous nervegrowth factor (NGF) and NGF receptor in experimental diabetic neuropathy // Exp Neurol. – 1994.
–V. 130(1). - P. 24-30.34. Lebed Y.V/, Orlovsky M.A., Nikonenko A.G., Ushakova G.A., Skibo G.G. Early reactionof astroglial cells in rat hippocampus to streptozotocin-induced diabetes // Neurosci Lett. – 2008. – V.444(2). - P. 181-185.35. Afsari Z.H., Renno W.M., Abd-El-Basset E. Alteration of glial fibrillary acidic proteinsimmunoreactivity in astrocytes of the spinal cord diabetic rats // Anat Rec (Hoboken). – 2008. – V.291(4). - P. 390-39936. Michel C., Boitard C., Bach J.F. Insulin autoantibodies in non-obese diabetic (NOD) mice// Clin Exp Immunol. – 1989. - V.
75(3). – P. 457-46037. Yu L., Robles D.T., Abiru N., Kaur P., Rewers M., Kelemen K., Eisenbarth G.S. Earlyexpression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for earlydetermination of subsequent diabetes // Proc Natl Acad Sci U S A. - 2000. V. 15;97(4). – P.
1701-170610238. Myers M.A., Laks M.R., Feeney S.J., Mandel T.E., Koulmanda M., Bone A., Barley J.,Rowley M.J., Mackay I.R. Antibodies to ICA512/IA-2 in rodent models of IDDM // J Autoimmun. 1998. – V. 11(3). - P. 265-27239.SchmidtR.E., DorseyD.A., BeaudetL.N.obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy:et.al.Non-a new experimentalmodel of diabetic autonomic neuropathy // Am J Pathol.
– 2003. – V. 163(5). - P. 2077-209140. Beauquis J., Homo-Delarche F., Revsin Y., De Nicola A.F., Saravia F. Brain alterations inautoimmune and pharmacological models of diabetes mellitus: focus on hypothalamic-pituitaryadrenocortical axis disturbances // Neuroimmunomodulation.
- 2008. – V. 15(1). - P. 61-6741. Смирнова О.М., Горелышева В.А., Дедов И.И., Характеристика фазы ремиссии привпервые выявленном инсулинзависимом сахарном диабете // Сахарный диабет. - 1999. - №1. с. 9-1242. Foulis A.K. Pancreatic pathology in type 1 diabetes in human // Novartis Found Symp. 2008. – V. 292. – P. 2-1343. Wen L., Green E.
A.,. Stratmann Th, Panosa A., et. al. In vivo diabetogenic action ofCD41 T lymphocytes requires Fas expression and is independent of IL-1 and IL-18 // Eur. J.Immunol. - 2011. - V. 41. - P. 1344–134444. Calderon B., Suri A., Unanue E. R.. In CD4_ T-Cell-Induced Diabetes, Macrophages Arethe Final Effector Cells that Mediate Islet β-cell killing. // Am.
J. Path., v. 169, №. 6, 2006. pp. 2137214745. Willox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G.. Analysis ofinflammation in human type 1 diabetes. // Clin. Exp. Imm. - 2008. - V. 155. - P. 173-181.46. Tanaka S., Nishida Y., Aida K. et.al.
Enterovirus infection, CXC chemokine ligand 10(CXCL10) and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1diabetes // Diabetes. - 2009. - V.58(10) - P. 2285-229147. Воробьев А.А., Быков А. С., Караулов А. В.
Иммунология и аллергология.//Практическая медицина. - 2006. - М. – 288 с.48. Eizirik D.L, Colli M.L., Ortis F. The role of inflammation in insulitis and beta-cell loss intype 1 diabetes // Nat Rev Endocrinol. - 2009. - V. 5(4). - P. 219-22649. Зак К.П., Попова В.В. Хемокины при сахарном диабете 1-го типа у человека (обзорлитературы и собственные данные) // Укр. Мед.
Часопис. - 2008. - Т.6 (68).- С. 69-7750. Aribi M., Moulessehoul S., Kendouci-Tani M., Benabadji A.B., Hichami A., Khan N.A.Relationship between interleukin-1beta and lipids in type 1 diabetic patients // Med Sci Monit. - 2007.– V. 13(8). - P. 372-37810351. Chatzigeorgiou A., Harokopos V., Mylona-Karagianni C., Tsouvalas E., Aidinis V.,Kamper E.F. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1diabetic patients over time // Ann Med. – 2010. - V. 42(6). - P. 426-43852. Erbağci A.B., Tarakçioğlu M., Coşkun Y., Sivasli E., Sibel Namiduru E.
Mediators ofinflammation in children with type I diabetes mellitus: cytokines in type I diabetic children // ClinBiochem. - 2001. - V. 34(8). - P. 645-65053. Pfleger C., Kaas A., Hansen L., Alizadeh B., Hougaard P., Holl R., Kolb H., Roep B.O.,Mortensen H.B., Schloot N.C. Relation of circulating concentrations of chemokine receptor CCR5ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes // ClinImmunol. - 2008. - V. – 128(1). – P.57-6554.
Zineh I., Beitelshees A.L., Silverstein J.H., Haller M.J. Serum monocyte chemoattractantprotein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1diabetes // Diabetes Care. - 2009. - V. 32(3). – P. 465-46755. Antonelli A., Fallahi P., Ferrari S.M., Pupilli C., d'Annunzio G., Lorini R., Vanelli M.,Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newlydiagnosed Type 1 diabetes: a longitudinal study // Diabet Med.
– 2008. – V. 25(11). – P. 1349-135356. Morii T. Fujita H, Narita T., Shimotomai T., Fujishima H., Yoshioka N., Imai H., KakeiM., Ito S. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabeticnephropathy // J Diabetes Complications. – 2003. - V. 17(1). – P. 11-15.57. Nicololetti F., Conget I, Di Mauro M., Di Marco .R, Mazzarino M.C., BendtzenK., Messina A., Gomis R. Serum concentrations of the interferon-gamma-inducible chemokine IP10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects atrisk of developing the disease // Diabetologia.
– 2002. – V. 45(8). P. - 1107-1110.58. Ozer G., Teker Z., Cetiner S., Yilmaz M., Topaloglu A.K., Onenli-Mungan N., Yüksel B.Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and theirsiblings // J Pediatr Endocrinol Metab. – 2003. - V.16(2). - P. 203-210.59. Lo H.C., Lin S.C., Wang Y.M. The relationship among serum cytokines, chemokine, nitricoxide, and leptin in children with type 1 diabetes mellitus // Clin Biochem. – 2004. - V. 37(8). - P.
66667260. Kimpimäki T., Kulmala P., Savola K., Kupila A., Korhonen S., Simell T., Ilonen J., SimellO, Knip M. Natural history of beta-cell autoimmunity in young children with increased geneticsusceptibility to type 1 diabetes recruited from the general population // J Clin Endocrinol Metab. –2002. – V. 87(10). - P. 4572-457961. Brooks-Worrell B.M., Nielson D., Palmer J.P. Insulin autoantibodies and insulinantibodies have similar binding characteristics // Proc Assoc Am Physicians. – 1999.
- V. 111(1). P. 92-10496.62. Vähäsalo P. Autoantibodies to insulin have similar affinity to that of antibodies toexogenous insulin but lower binding capacity // Eur J Clin Invest. – 1992. - V. 22(12). - P. 772-67663. Wichterle D., Stolba P., Bendlová B., Krnáková A. Anti-insulin antibodies and insulinresistance // Vnitr Lek. – 1995. – V. 41(2). – P. 146-15064.
Wiggin T. D., Sullivan K. A., Pop-Busui R. Amato A, et al. Elevated TriglyceridesCorrelate With Progression of Diabetic Neuropathy // Diabetes. – 2009. – V. 58. - P. 1634–1640.65. Dyck P.J., Litchy W.J. et al. Variables influences neuropathic endpoints.
The RochesterDiabetic Neuropathy Study of Health Subjects // Neurology. – 1995. - V. 45. - P. 1115–112166. Meh D., Denislic M. Subclinical neuropathy in type I diabetic children //Electroencephalography and clinical Neurophysiology. – 1998. - V. 109. – P. 274–28067. Karsidag S., Morali S., Sargin M., Salman S., Karsidag K., Us.O. Theelectrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1diabetes mellitus // Diabetes Res Clin Pract.
– 2005. V. 67(3). - P. 211-21968. Boucek P. Advanced Diabetic Neuropathy: A Point of no Return? // Rev Diabet Stud. –2006. – V. 3(3). - P. 143-15069. Vinik A.I., Anandacoomaraswamy D., Ullal J. Antibodies to neuronal structures: innocentbystanders or neurotoxins? // Diabetes Care. – 2005. - V. 28(8). - P.
2067-72.70. Luppi P., Cifarelli V., Wahren J. C-peptide and long-term complications of diabetes //Pediatric Diabetes. – 2011. V. 12. - P. 276–29271. Waksman B.H., Adams R.D. Allergic neuritis: an experimental disease of rabbits inducedby the injection of peripheral nervous tissue and adjuvants // J Exp Med. – 1955. – V. 102. - P.
213–23672. Савельев С.В., Барабанов В.М., Кривова Ю.С., Прощина А.Е. Неврогенныемеханизмы развития сахарного диабета 1-го типа // Архив патологии. - 2008.- N 6.- С. 9-1373. Teepker M., Munk K., Mylius V., Haag A., Möller J.C, Oertel W.H., Schepelmann K.Serum Concentrations of s100b and NSE in Migraine. // Headache. – 2009. – V. 49(2). - P. 245-25274. Морозова Ю.А., Камчатнов П.Р., Ахметжанова Л.Л.. Содержание белка S-100 ифактора некроза опухоли альфа в сыворотке крови больных дисциркуляторной энцефалопатией// Журнал неврологии и психиатрии.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
